Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score

BACKGROUND: Remdesivir was the first antiviral to show clinical benefit in patients with moderate-to-severe COVID-19. Previous trials demonstrated a faster time to recovery in hospitalized patients treated with remdesivir vs placebo. Current guidelines recommend treatment with remdesivir based on ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Sellers, Jacob, Chang, Jongwha, Jones, Jessica, Hintze, Trager D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806928/
https://www.ncbi.nlm.nih.gov/pubmed/36603741
http://dx.doi.org/10.1016/j.pupt.2022.102188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806928/
https://www.ncbi.nlm.nih.gov/pubmed/36603741
http://dx.doi.org/10.1016/j.pupt.2022.102188

Ejemplares similares